BioCancell, Pro-Pharmaceuticals to Develop New Cancer Treatment

BioCancell Therapeutics Inc. (BICL), an Israeli biotechnology company, and Pro-Pharmaceuticals Inc., the U.S. developer of technology to treat cancer, will collaborate to develop a treatment for the disease.

The two companies will join to test combination therapies to infect genes that enable cancer to survive and grow, Jerusalem- based BioCancell said in a statement to the Tel Aviv Stock Exchange today.

To contact the reporter on this story: Tal Barak in Tel Aviv at

To contact the editor responsible for this story: Daniel Hauck at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.